Use in treatment of aspergillosis has been reported. This makes them vulnerable to fungal diseases of the nose such as aspergillosis. Bennett was the first doctor to describe aspergillosis. Isavuconazole was recently FDA approved to treat invasive aspergillosis and invasive mucormycosis. These conditions, with the exception of aspergillosis, are easily prevented. The most common species among paranasal sinus infections associated with aspergillosis is "A. fumigatus". It causes allergic bronchopulmonary disease and chronic lung lesions that resemble aspergillosis. In dogs, aspergillosis is an uncommon disease typically affecting only the nasal passages (nasal aspergillosis). Typical examples of sapronotic agents are fungal such as coccidioidomycosis, histoplasmosis, aspergillosis, cryptococcosis, "Microsporum gypseum". Laboratory analysis is the only way to distinguish bird flu from aspergillosis. "A. lentulus" is an opportunistic human pathogen that causes invasive aspergillosis with high mortality rates. Examples of opportunistic mycoses include Candidiasis, Cryptococcosis and Aspergillosis. This includes aspergillosis, blastomycosis, coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis. Aspergillosis of the ear canal causes itching and occasionally pain. Prevention of aspergillosis involves a reduction of mold exposure via environmental infection-control.